Cardiovascular effects of SGLT-2 inhibitors: What we have learned from cardiovascular outcome trials and what we still need to understand

被引：11

作者：

Cavallari, Ilaria ^{[1
]}

Maddaloni, Ernesto ^{[2
,3
]}

机构：

[1] Campus Biomed Univ Rome, Dept Cardiovasc Sci, Rome, Italy

[2] Campus Biomed Univ Rome, Unit Endocrinol & Diabet, Dept Med, Via Alvaro Portillo 200, Rome, Italy

[3] Sapienza Univ Rome, Expt Med, Rome, Italy

来源：

DIABETES-METABOLISM RESEARCH AND REVIEWS | 2019年 / 35卷 / 04期

关键词：

cardiovascular disease; clinical trials; SGLT-2; inhibitors; HEART-FAILURE; EMPAGLIFLOZIN; MORTALITY; RISK;

D O I：

10.1002/dmrr.3124

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The recent results of the DECLARE-TIMI 58 trial forces a profound reflection about the cardiovascular protection conferred by SGLT-2 inhibitors. DECLARE-TIMI 58, the largest cardiovascular outcome trial in diabetes, failed to show a significant reduction in the risk of major adverse cardiovascular events (MACEs) conferred by dapagliflozin compared with placebo. However, a lower rate of hospitalization for heart failure was reported. Whilst the lack of benefits on MACE may seem in contrast with the results of previous SGLT-2 inhibitors cardiovascular outcome trials, DECLARE clearly delineates the real cardiovascular effects of SGLT-2 inhibitors, which mainly tackle heart failure. Differences in study design and population enrolled are crucial to correctly value each molecule and to translate results of clinical trials in daily clinical practise.

引用

页数：3

共 12 条

[1] Adaptive Designs for Clinical Trials [J].

Bhatt, Deepak L. ;

Mehta, Cyrus .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (01) :65-74

[2] Renal, metabolic and cardiovascular considerations of SGLT2 inhibition [J].

DeFronzo, Ralph A. ;

Norton, Luke ;

Abdul-Ghani, Muhammad .

NATURE REVIEWS NEPHROLOGY, 2017, 13 (01) :11-26

[3] Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrumof heart failure risk in the EMPA-REG OUTCOME® trial [J].

Fitchett, David ;

Butler, Javed ;

van de Borne, Philippe ;

Zinman, Bernard ;

Lachin, John M. ;

Wanner, Christoph ;

Woerle, Hans J. ;

Hantel, Stefan ;

George, Jyothis T. ;

Johansen, Odd Erik ;

Inzucchi, Silvio E. ;

Aizenberg, D. ;

Ulla, M. ;

Waitman, J. ;

De Loredo, L. ;

Farias, J. ;

Fideleff, H. ;

Lagrutta, M. ;

Maldonado, N. ;

Colombo, H. ;

Ferre Pacora, F. ;

Wasserman, A. ;

Maffei, L. ;

Lehman, R. ;

Selvanayagam, J. ;

d'Emden, M. ;

Fasching, P. ;

Paulweber, B. ;

Toplak, H. ;

Luger, A. ;

Drexel, H. ;

Prager, R. ;

Schnack, C. ;

Schernthaner, G. ;

Fliesser-Goerzer, E. ;

Kaser, S. ;

Scheen, A. ;

Van Gaal, L. ;

Hollanders, G. ;

Kockaerts, Y. ;

Capiau, L. ;

Chachati, A. ;

Persu, A. ;

Hermans, M. ;

Vantroyen, D. ;

Vercammen, C. ;

Van de Borne, P. ;

Mathieu, C. ;

Benhalima, K. ;

Lienart, F. .

EUROPEAN HEART JOURNAL, 2018, 39 (05) :363-370

[4] Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial [J].

Fitchett, David ;

Zinman, Bernard ;

Wanner, Christoph ;

Lachin, John M. ;

Hantel, Stefan ;

Salsali, Afshin ;

Johansen, Odd Erik ;

Woerle, Hans J. ;

Broedl, Uli C. ;

Inzucchi, Silvio E. ;

Aizenberg, D. ;

Ulla, M. ;

Waitman, J. ;

De Loredo, L. ;

Farias, J. ;

Fideleff, H. ;

Lagrutta, M. ;

Maldonado, N. ;

Colombo, H. ;

Ferre Pacora, F. ;

Wasserman, A. ;

Maffei, L. ;

Lehman, R. ;

Selvanayagam, J. ;

d'Emden, M. ;

Fasching, P. ;

Paulweber, B. ;

Toplak, H. ;

Luger, A. ;

Drexel, H. ;

Prager, R. ;

Schnack, C. ;

Schernthaner, G. ;

Fliesser-Goerzer, E. ;

Kaser, S. ;

Scheen, A. ;

Van Gaal, L. ;

Hollanders, G. ;

Kockaerts, Y. ;

Capiau, L. ;

Chachati, A. ;

Persu, A. ;

Hermans, M. ;

Vantroyen, D. ;

Vercammen, C. ;

Van de Borne, P. ;

Mathieu, C. ;

Benhalima, K. ;

Lienart, F. ;

Mortelmans, J. .

EUROPEAN HEART JOURNAL, 2016, 37 (19) :1526-1534

[5] Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes [J].

Holman, Rury R. ;

Bethel, M. Angelyn ;

Mentz, Robert J. ;

Thompson, Vivian P. ;

Lokhnygina, Yuliya ;

Buse, John B. ;

Chan, Juliana C. ;

Choi, Jasmine ;

Gustavson, Stephanie M. ;

Iqbal, Nayyar ;

Maggioni, Aldo P. ;

Marso, Steven P. ;

Ohman, Peter ;

Pagidipati, Neha J. ;

Poulter, Neil ;

Ramachandran, Ambady ;

Zinman, Bernard ;

Hernandez, Adrian F. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (13) :1228-1239

[6] Predicting mortality among patients hospitalized for heart failure - Derivation and validation of a clinical model [J].

Lee, DS ;

Austin, PC ;

Rouleau, JL ;

Liu, PP ;

Naimark, D ;

Tu, JV .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (19) :2581-2587

[7] Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes [J].

Marso, Steven P. ;

Daniels, Gilbert H. ;

Brown-Frandsen, Kirstine ;

Kristensen, Peter ;

Mann, Johannes F. E. ;

Nauck, Michael A. ;

Nissen, Steven E. ;

Pocock, Stuart ;

Poulter, Neil R. ;

Ravn, Lasse S. ;

Steinberg, William M. ;

Stockner, Mette ;

Zinman, Bernard ;

Bergenstal, Richard M. ;

Buse, John B. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (04) :311-322

[8] Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes [J].

Neal, Bruce ;

Perkovic, Vlado ;

Mahaffey, Kenneth W. ;

de Zeeuw, Dick ;

Fulcher, Greg ;

Erondu, Ngozi ;

Shaw, Wayne ;

Law, Gordon ;

Desai, Mehul ;

Matthews, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (07) :644-657

[9] Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs [J].

Patti, Giuseppe ;

Cavallari, Ilaria ;

Andreotti, Felicita ;

Calabro, Paolo ;

Cirillo, Plinio ;

Denas, Gentian ;

Galli, Mattia ;

Golia, Enrica ;

Maddaloni, Ernesto ;

Marcucci, Rossella ;

Parato, Vito Maurizio ;

Pengo, Vittorio ;

Prisco, Domenico ;

Ricottini, Elisabetta ;

Renda, Giulia ;

Santilli, Francesca ;

Simeone, Paola ;

De Caterina, Raffaele .

NATURE REVIEWS CARDIOLOGY, 2019, 16 (02) :113-130

[10] Predictors of mortality and morbidity in patients with chronic heart failure [J].

Pocock, SJ ;

Wang, DL ;

Pfeffer, MA ;

Yusuf, S ;

McMurray, JJV ;

Swedberg, KB ;

Östergren, J ;

Michelson, EL ;

Pieper, KS ;

Granger, CB .

EUROPEAN HEART JOURNAL, 2006, 27 (01) :65-75

← 1 2 →